Incidence of toxic liver lesions due to Gravistat
Link, H.; Metzner, C.; Ziesenhenn, K.
Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 33(6): 187-189
1978
ISSN/ISBN: 0044-2542 PMID: 645155 Document Number: 136920
A study of the hepatic effects of Gravistat on 240 women is presented. 200 of the women had previously used either Ovosiston or Non-Ovlon continually for an average of 5.6 years, while the remaining 40 had used no hormonal contraceptives for the preceeding 3 months. After 3 weeks of Gravistat use, GOT, GPT, LP-X, and cholesterol levels were taken. 1/4 of the women in both groups showed pathological serum transaminase levels, and the cholesterol levels in both groups were within normal levels. 10 of the women who had previously used hormonal contraceptives, and none from the other group, showed a positive LP-X. A hepatological examination, including a liver biopsy, was performed on 30 of the women with pathological transaminase levels and/or positive LP-X. Pathological conditions (toxic hepatosis, infectious hepatitis, fatty liver) were found in 11 of those cases, while the rest showed metabolic activation. Intrahepatic cholestasis does not seem to be the major factor in the liver damage.